{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 457657906
| IUPAC_name = (''E'')-1-''N{{'}}''-[2-[<nowiki />[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-''N''-methyl-2-nitroethene-1,1-diamine
| image = Nizatidine.svg
| width = 260

<!--Clinical data-->
| tradename = Axid
| Drugs.com = {{drugs.com|monograph|nizatidine}}
| MedlinePlus = a694030
| licence_US = Nizatidine
| pregnancy_AU = B3
| legal_AU = S4
| legal_UK = POM
| legal_US = Rx
| legal_US_comment = and OTC<ref name=LiverTox/>
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability = >70%
| protein_bound = 35%
| metabolism = [[Liver|Hepatic]]
| elimination_half-life = 1–2 hours
| excretion = [[Kidney|Renal]]

<!--Identifiers-->
| IUPHAR_ligand = 7248
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 76963-41-2
| ATC_prefix = A02
| ATC_suffix = BA04
| ATC_supplemental =  
| PubChem = 3033637
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00585
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2298266
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = P41PML4GHR
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00440
| ChEBI_Ref = {{ebicite|changed|EBI}} 
| ChEBI = 7601
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 653

<!--Chemical data-->
| C=12 | H=21 | N=5 | O=2 | S=2
| molecular_weight = 331.46 g/mol
| smiles = [O-][N+](=O)\C=C(/NC)NCCSCc1nc(sc1)CN(C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6+
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = SGXXNSQHWDMGGP-IZZDOVSWSA-N
}}

'''Nizatidine''' is a histamine [[H2 antagonist|H<sub>2</sub> receptor antagonist]] that inhibits [[gastric acid|stomach acid]] production, and is commonly used in the treatment of [[peptic ulcer]] disease and [[gastroesophageal reflux disease]]. It was developed by [[Eli Lilly and Company|Eli Lilly]] and is marketed under the brand names '''Tazac''' and '''Axid'''.

==Clinical use==
{{main|H2 antagonist}}
Nizatidine is used to treat [[duodenal ulcers]], [[gastric ulcers]], and [[gastroesophageal reflux disease]] (GERD/GORD), and to prevent [[stress ulcer]]s.<ref name=LiverTox>{{cite web|url=http://livertox.nih.gov/Nizatidine.htm |title=Nizatidine |publisher=Livertox.nih.gov |date= |accessdate=2015-10-11}}</ref>

==Adverse effects==
Side effects are uncommon, usually minor, and include diarrhea, constipation, fatigue, drowsiness, headache, and muscle aches.<ref name=LiverTox/>

==History and development==
Nizatidine was developed by [[Eli Lilly and Company|Eli Lilly]], and was first marketed in 1987. It is considered to be equipotent with [[ranitidine]] and differs by the substitution of a [[thiazole]] ring in place of the [[furan]] ring in ranitidine. In September 2000, Eli Lilly announced they would sell the sales and marketing rights for Axid to [[Reliant Pharmaceuticals]].<ref name="encyclopedia">[http://www.encyclopedia.com/doc/1G1-65062714.html?Q=%22axid%22 ] {{webarchive |url=https://web.archive.org/web/20080526223021/http://www.encyclopedia.com/doc/1G1-65062714.html?Q=%22axid%22 |date=May 26, 2008 }}</ref> Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA).<ref name="reliant2004">[http://www.reliantrx.com/investor/press_releases/072604.htm] {{webarchive |url=https://web.archive.org/web/20131226093839/http://www.reliantrx.com/investor/press_releases/072604.htm |date=December 26, 2013 }}</ref> However, a year later, they sold rights of the Axid Oral Solution (including the issued patent<ref>{{cite web|url=http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6930119.PN.&OS=PN/6930119&RS=PN/6930119 |title=United States Patent: 6930119 |publisher=Patft.uspto.gov |date= |accessdate=2015-10-11}}</ref> protecting the product) to Braintree Laboratories.<ref name="reliant2005">[http://www.reliantrx.com/investor/press_releases/063005.htm] {{webarchive |url=https://web.archive.org/web/20070814071007/http://www.reliantrx.com/investor/press_releases/063005.htm |date=August 14, 2007 }}</ref>

Nizatidine proved to be the last new histamine H<sub>2</sub> receptor antagonist introduced prior to the advent of [[proton pump inhibitor]]s.{{citation needed|date=January 2016}}

==See also==
* [[Famotidine]] (Pepcid) — another popular H<sub>2</sub> receptor antagonist

==References==
{{Reflist}}

==External links==
* [http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=2929 Dailymed.nlm.nih.gov]
* [http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=AXID Axid @ FDA]
* [http://www.axidos.com/ Axid Oral Solution]

{{H2-receptor antagonist}}
{{Histaminergics}}

[[Category:Eli Lilly and Company]]
[[Category:H2 receptor antagonists]]
[[Category:Nitroethenes]]
[[Category:Thiazoles]]
[[Category:Thioethers]]